Phase III study, Double blind randomized of lenalidomide (Revlimid®) maintenance vs. placebo in responding elderly patients with diffuse large B-cell lymphoma and treated with R-CHOP in first line. (REMARC) LYSARC /Grupos cooperativos europeos.
| Investigador Principal | Dra. Dolores Caballero |
| Estado del Protocolo | Cerrado reclutamiento |